Antiplatelet Therapy

Transient Ischemic Attacks

Volumn , Issue , 2007, Pages 233-252

  Schneck, Michael J ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Antiplatelet therapy; Aspirin; Aspirin and carotid endarterectomy (ACE) trial; Meta analyses; Transient ischemic attacks

Indexed keywords

EID: 65549149116     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470988442.ch10     Document Type: Chapter

References (60)

1. Schneck MJ. Anticoagulation for stroke prevention. In: Gorelick PB, Alter M, eds. The Prevention of Stroke. New York: Parthenon Publishing Group, 2002: 208-22.
2. Mohr JP, Thompson. JL, Lazar RM. Warfarin-Aspirin Recurrent Stroke Study Group, a comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-51.
3. Anonymous. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-65.
4. Patrono C, Coller. B, Dalen JE et al. Platelet-active drugs: the relationships among dose, effectiveness and side-effects. Chest 2001; 119 (Suppl. 1): 39S-63S.
5. Roth GH, Calverley. DC. Aspirin, platelets and thrombosis: theory and practice. Blood 1994; 83: 885-98.
6. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
7. Stassen JM, Nystrom A. A historical overview of hemostasis, thrombosis, and antithrombotic therapy. Ann Plast Surg 1997; 38: 317-29.
8. Millikan C, Futrell. N. The strange story of aspirin and the prevention of stroke. J Stroke Cerebrovasc Dis 1995; 5: 248-54.
9. Schafer A. Antiplatelet therapy. Am J Med 1996; 101: 199-209.
10. Dutch TIA Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-6.
11. Pettigrew LC. Antithrombotic drugs for secondary stroke prophylaxis. Pharmacotherapy 2001; 21: 452-63.
12. Babu KS, Salvi SS. Aspirin and asthma. Chest 2000; 118: 1470-6.
13. Hart RG, Harrison. MJG. Aspirin wars: the optimal dose of aspirin to prevent stroke. Stroke 1996; 27: 585-7.
14. Barnett HJM, Kaste M, Meldrum H, Eliasziw M. Aspirin dose in stroke preven-tion: beautiful hypotheses slain by ugly facts. Stroke 1996; 27: 588-92.
15. Savon JJ, Allen ML, DiMarino AJ et al. Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastroenterol 1995; 90: 581-5.
16. Roderick J, Wilkes HC, Mead TW. The gastrointestinal toxicity of aspirin: aAn overview of randomized controlled trials. J Clin Pharmacol 1993; 35: 219-26.
17. Fields W, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977; 8: 301-6.
18. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53-9.
19. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J 1988; 296: 316-20.
20. UK-TIA Study Group. United Kingdom Transient Ischemic Attack (UK-TIA.) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-54.
21. SALT Collaborative Group. Swedish Aspirin Low dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebral ischemic events. Lancet 1991; 338: 1345-9.
22. Antiplatelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-31.
23. Helgason CM, Tortorice KL, Winker SR et al. Aspirin response and failure in cerebral infarction. Stroke 1993; 24: 345-50.
24. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995; 332: 238-48.
25. Taylor WD, Barnett HJM, Haynes RB et al. (ACE Collaborators). Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. Lancet 1999; 353: 2179-84.
26. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
27. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
28. Albers GW, Tijssen JG. Antiplatelet therapy: new foundations for optimal treatment decisions. Neurology 1999; 53 (Suppl. 4): S25-S31.
29. Albers GW, Amarenco P, Easton JD et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119 (Suppl. 1): 300S-320S.
30. Gelmers H, Tijssen JG. Platelet antiaggregants in secondary prevention after stroke: does dipyridamole add to the effect of aspirin? J Stroke Cerebrovasc Dis 1993; 3: 115-20.
31. Johnson ES, Lanes SF, Wentworth CE et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999; 159: 1248-53.
32. Quinn MJ, Fitzgerald. DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-72.
33. Haas WK, Easton JD, Adams HP Jr. et al. A randomized trial comparing ticlo-pidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501-7.
34. Hankey GJ, Sudlow CLM, Dunbabin DW. Thienopyridines or aspirin to pre-vent stroke and other serious vascular events in patients at high risk of vascular disease? A systemic review of the evidence from randomized trials. Stroke 2000; 31: 1779-84.
35. Ticlopidine Aspirin Stroke Study Group. Ticlopidine versus aspirin for stroke prevention: on-treatment results from Ticlopidine Aspirin Stroke Study. J Stroke Cerebrovasc Dis 1993; 3: 168-76.
36. Bennet CL, Weinberg. PD, Rozenberg-Ben-Dor K et al. Thrombotic thrombo-cytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998; 128: 541-4.
37. Bennet CL, Connors JM, Carwile JM et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-7.
38. Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-20.
39. Harbison JW, Ticlopidine Aspirin Stroke Study Group. Ticlopidine versus aspirin for the prevention of recurrent stroke: analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Stroke 1992; 23: 1723-7.
40. Grotta JC, Norris JW, Kamen B. Prevention of stroke with ticlopidine: who benefits most? TASS baseline and angiographic data subgroup. Neurology 1992; 42: 111-5.
41. Weisberg LA, Ticlopidine Aspirin Stroke Study Group. The efficacy and safety of ticlopidine and aspirin in nonwhites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. Neurology 1993; 43: 27-31.
42. Gorelick PB, Leurgans S, Richardson D et al. African-American Antiplatelet Stroke Prevention Study (AAASPS): clinical trial design. J Stroke Cerebrovasc Dis 1998; 7: 426-34.
43. CAPRIE Steering Committee. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
44. Easton JD. Future perspectives for optimizing oral antiplatelet therapy. Cerebrovasc Dis 2001; 11 (Suppl. 2): 23-8.
45. Hacke W. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 2002; 13 (Suppl. 1): 22-6.
46. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med 2001; 345: 494-502.
47. Albers GW, Amarenco P. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascular patients. Stroke 2001; 32: 2948-9.
48. Wilterdink JL, Easton JD. Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 1999; 56: 1087-92.
49. ESPS2 Study Group. Safety. European Stroke Prevention Study 2. J Neurol Sci 1997; 151: S41-51.
50. Bousser MG, Eschwege E, Haguenau M et al. 'AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral cerebral ischemia. Stroke 1983; 14: 5-14.
51. European Stroke Prevention Study Group. European Stroke Prevention Study. Stroke 1990; 21: 1122-30.
52. ESPS2 Study Group. Primary endpoints: European Stroke Prevention Study 2. J Neurol Sci 1997; 151 (Suppl.): S13-26.
53. ESPS2 Study Group. Secondary Endpoints: European Stroke Prevention Study 2. J Neurol Sci 1997; 151: S27-S37.
54. Masuhr F, Busch M, Einhaupl KM. Differences in medical and surgical therapy for stroke prevention between leading experts in North America and Western Europe. Stroke 1998; 29: 339-45.
55. Anonymous. Internalanalgesic antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Federal Register 1999; 64: 49652-5.
56. Albers GW. Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients? Neurology 2000; 54: 1022-8.
57. Samsa GP, Matchar DB, Goldstein LB et al. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J 1998; 136: 703-13.
58. Scott-Levin Associates. Prescription Audit Calendar Year 2000. 2000.
59. Gorelick PB, Richardson D, Kelly M et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients. JAMA 2003; 289: 2947-57.
60. Sarasin F, Gaspoz J-M, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med 2000; 160: 2773-8.